levodopa has been researched along with d-alpha tocopherol in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 19 (57.58) | 18.2507 |
| 2000's | 5 (15.15) | 29.6817 |
| 2010's | 7 (21.21) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Nag, D | 1 |
| Levivier, M; Przedborski, S | 1 |
| Fahn, S | 1 |
| Factor, SA; Sanchez-Ramos, JR; Weiner, WJ | 1 |
| Abe, T; Hamato, F; Saheki, M; Sasaki, K; Takahashi, S; Tohgi, H | 1 |
| Carter, J; Fahn, S; Gauthier, S; Goetz, CG; Golbe, LI; Jankovic, J; Koller, W; Lang, AE; McDermott, MP; Olanow, CW | 1 |
| Calne, DB; Uitti, RJ; Vingerhoets, FJ | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Olanow, CW | 1 |
| Heinonen, E; Mäki-Ikola, O | 1 |
| Lai, CT; Yu, PH | 1 |
| Cui, L; LeWitt, P; Oakes, D | 1 |
| Chang, HC; Chen, RS; Liao, KK; Lu, CS; Tsai, CH | 1 |
| Jiménez-Jiménez, FJ; Molina, JA | 1 |
| Koller, WC | 1 |
| Althaus, JS; Fici, GJ; VonVoigtlander, PF | 1 |
| Carvey, PM; Ling, ZD; Robie, HC; Tong, CW | 1 |
| Asanuma, M; Furuta, H; Miyazaki, I; Ogawa, N; Sogawa, CA; Sogawa, N | 1 |
| Arlt, S; Beisiegel, U; Buhmann, C; Kontush, A; Möller-Bertram, T; Oechsner, M; Sperber, S; Stuerenburg, HJ | 1 |
| Jankovic, J; Olanow, CW | 1 |
| Hachinohe, M; Matsumoto, H | 1 |
| Quach, HT; Smith, WE; Vatassery, GT | 1 |
| Hauser, RA | 1 |
| Bennett, JW; Inamdar, AA; Masurekar, P | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Jodko-Piórecka, K; Litwinienko, G | 1 |
| Ahmadouk, NA; Gopaluni, S; Sherif, M | 1 |
| Alam, T; Ali, J; Baboota, S; Gaba, B; Haider, MF; Khan, T; Parvez, S | 1 |
| Bhuvanendran, S; Magalingam, KB; Radhakrishnan, AK; Ramdas, P; Selvaduray, KR; Somanath, SD | 1 |
6 review(s) available for levodopa and d-alpha tocopherol
| Article | Year |
|---|---|
[Current therapeutic approach in Parkinson disease].
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E | 1992 |
[Neuroprotective and neurorestorative therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Apoptosis; Brain Tissue Transplantation; Chelation Therapy; Corpus Striatum; Dopamine; Erythrocytes; Free Radicals; Gangliosides; Genetic Therapy; Glutathione Peroxidase; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxidative Stress; Parkinson Disease; Selegiline; Selenium; Vitamin E | 1997 |
Neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E | 1998 |
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E | 2005 |
Early pharmacologic treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Ubiquinone; Vitamin E | 2010 |
Interventions for chronic kidney disease-associated restless legs syndrome.
Topics: Amines; Anticonvulsants; Ascorbic Acid; Cyclohexanecarboxylic Acids; Dopamine Agonists; Exercise Therapy; Gabapentin; gamma-Aminobutyric Acid; Humans; Indoles; Iron-Dextran Complex; Levodopa; Quality of Life; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Resistance Training; Restless Legs Syndrome; Vitamin E; Vitamins | 2016 |
7 trial(s) available for levodopa and d-alpha tocopherol
| Article | Year |
|---|---|
An open trial of high-dosage antioxidants in early Parkinson's disease.
Topics: Adult; Aged; Ascorbic Acid; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Vitamin E | 1991 |
Vitamin E therapy in Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Retrospective Studies; Vitamin E | 1990 |
Effect of deprenyl on the progression of disability in early Parkinson's disease.
Topics: Activities of Daily Living; Clinical Trials as Topic; Drug Therapy, Combination; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline; Vitamin E | 1989 |
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
Topics: Adult; Age Factors; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Risk Factors; Selegiline; Sex Factors; Vitamin E | 1995 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
Topics: Activities of Daily Living; Adult; Aged; Antioxidants; Antiparkinson Agents; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome; Vitamin E | 1997 |
20 other study(ies) available for levodopa and d-alpha tocopherol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Therapy of Parkinson's disease: are we at the end of the road?
Topics: Antiparkinson Agents; Dopamine Agents; Humans; India; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E | 1992 |
Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment.
Topics: Aged; Glutathione; Glutathione Disulfide; Humans; Levodopa; Middle Aged; Parkinson Disease; Vitamin E | 1995 |
Deprenyl and the issue of neuroprotection.
Topics: Antioxidants; Cell Survival; Clinical Trials as Topic; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Neurons; Parkinson Disease; Selegiline; Substantia Nigra; Vitamin E | 1994 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
A 61-year-old man with Parkinson's disease.
Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E | 1996 |
Study design problems of DATATOP study analysis.
Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Placebos; Randomized Controlled Trials as Topic; Selegiline; Vitamin E | 1996 |
Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors.
Topics: Ascorbic Acid; Catalase; Cell Survival; Deferoxamine; Dopamine; Levodopa; Lipid Peroxidation; Neuroblastoma; Oxidative Stress; Superoxide Dismutase; Tumor Cells, Cultured; Vitamin E | 1997 |
Acanthocytosis and spinocerebellar degeneration: a new association?
Topics: Acanthocytes; Adult; Anticonvulsants; Antiparkinson Agents; Carbidopa; Cerebellum; Clonazepam; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Male; Spinocerebellar Degenerations; Videotape Recording; Vitamin E | 1997 |
Pharmacological approaches to counter the toxicity of Dopa.
Topics: Animals; Benzothiazoles; Cells, Cultured; Cerebellum; Cytoplasmic Granules; Glutathione; Levodopa; Neuroprotective Agents; Pramipexole; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Selegiline; Thiazoles; Vitamin E | 1998 |
Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Topics: Animals; Antioxidants; Benzothiazoles; Cell Count; Cell Survival; Cells, Cultured; Culture Media, Conditioned; Dopamine Agents; Dopamine Agonists; Levodopa; Mesencephalon; Neuroprotective Agents; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles; Tyrosine 3-Monooxygenase; Vitamin E | 1999 |
Antioxidants protect against dopamine-induced metallothionein-III (GIF) mRNA expression in mouse glial cell line (VR-2g).
Topics: Adrenergic Agents; Adrenergic alpha-Agonists; Animals; Antioxidants; Ascorbic Acid; Cell Line; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Glutathione; Glycerol-3-Phosphate Dehydrogenase (NAD+); Glycerolphosphate Dehydrogenase; Levodopa; Metallothionein; Mice; Neuroglia; Norepinephrine; Oxidopamine; Protein Isoforms; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vitamin E | 2000 |
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication.
Topics: Adult; alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Biomarkers; Brain; Dopamine; Female; Humans; Levodopa; Lipoproteins; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reference Values; Sulfhydryl Compounds; Ubiquinone; Up-Regulation | 2004 |
Involvement of reactive oxygen species generated from melanin synthesis pathway in phytotoxicty of L-DOPA.
Topics: alpha-Tocopherol; Antioxidants; Ascorbic Acid; Daucus carota; Dopamine; Lactuca; Levodopa; Lipid Peroxidation; Melanins; Oxidative Stress; Plant Roots; Poaceae; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances; Time Factors | 2005 |
Effect of oxidative stress induced by L-dopa on endogenous antioxidants in PC-12 cells.
Topics: alpha-Tocopherol; Animals; Antioxidants; Ascorbic Acid; Dopamine Agents; Drug Interactions; Levodopa; Oxidative Stress; PC12 Cells; Rats | 2006 |
Neurotoxicity of fungal volatile organic compounds in Drosophila melanogaster.
Topics: Air Pollution; Animals; Dopamine; Drosophila melanogaster; Environmental Monitoring; Fungi; Green Fluorescent Proteins; Housing; Levodopa; Locomotion; Male; Models, Animal; Nervous System; Neurons; Neurotoxins; Plant Extracts; Vitamin E; Volatile Organic Compounds | 2010 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Antioxidant activity of dopamine and L-DOPA in lipid micelles and their cooperation with an analogue of α-tocopherol.
Topics: alpha-Tocopherol; Antioxidants; Catecholamines; Chromans; Dopamine; Dopamine Agents; Free Radical Scavengers; Humans; Kinetics; Levodopa; Linoleic Acids; Lipid Peroxidation; Liposomes; Micelles; Oxidation-Reduction; Oxidative Stress; Oxygen Consumption | 2015 |
Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson's Disease Model.
Topics: Administration, Intranasal; Animals; Antioxidants; Behavior, Animal; Emulsions; Female; Flavanones; Levodopa; Male; Nanoparticles; Oxidative Stress; Oxidopamine; Parkinson Disease; Particle Size; Rats; Rats, Wistar; Solubility; Viscosity; Vitamin E | 2019 |
Tocotrienol-Rich Fraction and Levodopa Regulate Proteins Involved in Parkinson's Disease-Associated Pathways in Differentiated Neuroblastoma Cells: Insights from Quantitative Proteomic Analysis.
Topics: Chromatography, Liquid; Humans; Levodopa; Neuroblastoma; Parkinson Disease; Proteomics; Tandem Mass Spectrometry; Tocotrienols; Vitamin E | 2022 |